CRISPR Therapeutics AGCRSP
Market cap
$4.8B
P/E ratio
| 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Depreciation & amortization | 1 | 3 | 4 | 5 | 9 | 18 | 24 | 20 | 19 |
| Stock-based compensation | 11 | 19 | 35 | 44 | 66 | 102 | 98 | 81 | 87 |
| Cash from operations | -55 | -70 | -96 | 57 | -238 | 539 | -496 | -260 | -143 |
| Capital expenditures | -3 | -8 | -3 | -7 | -18 | -82 | -37 | -9 | -2 |
| Cash from investing | 32 | -8 | -3 | 1 | -541 | -1,035 | -259 | 375 | -280 |
| Repurchases of common stock | - | - | 0 | - | - | - | - | - | - |
| Cash from financing | 183 | 3 | 316 | 431 | 1,016 | 251 | 39 | 63 | 332 |
| Free cash flow | |||||||||
| FCF margin (%) |